Pfizer 2Q adj. profit beats, revenue misses Street’s view; reiterates 2013 outlook

NEW YORK, N.Y. – Pfizer’s second-quarter net income more than quadrupled, helped by the sale of its animal health business.

The drug company earned $14.1 billion, or $1.98 per share. That compares with $3.25 billion, or 43 cents per share, a year earlier.

Excluding a gain related to the sale of its remaining stake in Zoetis Inc. and other one-time items, earnings were 56 cents per share, a penny better than Wall Street had expected.

Revenue fell 7 per cent to $12.97 billion from $14 billion partly due to generic competition and the loss of exclusivity on Lipitor in Europe. That’s just short of the $13.21 billion analysts were expecting.

The New York company maintained its full-year adjusted earnings outlook of $2.10 to $2.20 per share. Analysts forecast $2.16 per share.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.